XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC). A total of 50 patients with MCRC aged ⩾70 years received oxaliplatin 130 mg m(−2) on day...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Feliu, J, Salud, A, Escudero, P, Lopez-Gómez, L, Bolaños, M, Galán, A, Vicent, J-M, Yubero, A, Losa, F, De Castro, J, de Mon, M Á, Casado, E, González-Barón, M
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 2006
主題:
Clinical Study
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361238/
https://ncbi.nlm.nih.gov/pubmed/16552438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603047
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍